Clinical Trials · NCT00542984

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Name: Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teriparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 70
Start date: Aug 2003
Locations: 1 site, South Korea
Primary endpoint: To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.

View Teriparatide compound reference